(MENAFN- EIN Presswire) With no approved therapies, companies can cater to the existing unmet needs of novel therapies and crack the code for further traumatic brain injury treatment.
LAS VEGAS, NEVADA, UNITED STATES, April 3, 2024 /EINPresswire / -- DelveInsight's“Traumatic Brain Injury Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Traumatic Brain Injury, historical and forecasted epidemiology as well as the Traumatic Brain Injury market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Traumatic Brain Injury market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Traumatic Brain Injury Market Forecast
Some of the key facts of the Traumatic Brain Injury Market Report:
The Traumatic Brain Injury market size is anticipated to grow with a significant CAGR during the study period (2019-2032).
According to DelveInsight's estimates, the US accounted for the highest number of patients with traumatic brain injury among the 7MM countries in 2022.
Key Traumatic Brain Injury Companies: Life Molecular Imaging SA, Hope Biosciences, Merz Pharmaceuticals GmbH, Vasopharm GmbH, Pinteon Therapeutics, Omniscient Neurotechnology, Pfizer, Supernus Pharmaceuticals, Inc., Solstice Neurosciences, Ipsen, POLYSAN Scientific & Technological Pharmaceutical Company, American CryoStem Corporation, and others
Key Traumatic Brain Injury Therapies: [18F]PI-2620, HB-adMSCs, NT 201, VAS203 (Ronopterin), PNT001, and others
The Traumatic Brain Injury market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Traumatic Brain Injury pipeline products will significantly revolutionize the Traumatic Brain Injury market dynamics.
Traumatic Brain Injury Overview
Traumatic Brain Injury (TBI) occurs due to head trauma, which includes impacts, blows, or the penetration of foreign objects into the skull and brain tissue. The primary radiological assessment method for TBI cases is computed tomography scanning, commonly known as a CT or CAT scan. CT scans are simple to conduct and highly proficient in detecting crucial indicators such as bleeding and fractures, both of which are essential in evaluating medical trauma. While some experts previously recommended plain skull X-rays for individuals experiencing mild neurological symptoms, most medical centers in the United States now have convenient access to CT scans, which offer superior accuracy. As a result, the routine use of skull X-rays for TBI patients has diminished.
Traumatic Brain Injury Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Traumatic Brain Injury Epidemiology Segmentation:
The Traumatic Brain Injury market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
Total Traumatic Brain Injury Incident Cases
Incident Cases of Traumatic Brain Injury by Age Group
Traumatic Brain Injury Severity-specific Cases
Traumatic Brain Injury Gender-specific Cases
Download the report to understand which factors are driving Traumatic Brain Injury epidemiology trends @ Traumatic Brain Injury Epidemiology Forecast
Traumatic Brain Injury Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Traumatic Brain Injury market or expected to get launched during the study period. The analysis covers Traumatic Brain Injury market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Traumatic Brain Injury Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Traumatic Brain Injury Therapies and Key Companies
Bevacizumab: Dana-Farber Cancer Institute
[18F]PI-2620: Life Molecular Imaging SA
HB-adMSCs: Hope Biosciences
NT 201: Merz Pharmaceuticals GmbH
VAS203 (Ronopterin): Vasopharm GmbH
PNT001: Pinteon Therapeutics
Discover more about therapies set to grab major Traumatic Brain Injury market share @ Traumatic Brain Injury Treatment Landscape
Traumatic Brain Injury Treatment Market
There are numerous treatment options available to assist individuals in their recovery journey from Traumatic Brain Injury (TBI), aiming to alleviate physical, emotional, and cognitive difficulties commonly associated with TBI. Medications play a crucial role in managing TBI symptoms and reducing the risk of related complications, categorized into two groups: those utilized immediately after TBI and those addressing ongoing symptoms and recovery challenges. These include anti-anxiety drugs, anticoagulants, anticonvulsants, antidepressants, diuretics, muscle relaxants, and stimulants.
Antidepressant medications, such as citalopram, amitriptyline, paroxetine, sertraline, among others, are believed to impact neurotransmitter levels in the brain, influencing the brain's response to these chemical messengers. Conversely, anticonvulsant drugs like sodium valproate, gabapentin, topiramate, and carbamazepine suppress excessive neuronal firing to prevent seizures and their spread within the brain, thus guarding against potential seizures.
Pain management drugs like acetaminophen, ibuprofen, and naproxen sodium are administered to alleviate TBI-induced pain and manage associated symptoms. Medications targeting the motor system, such as baclofen, tizanidine, or cyclobenzaprine, aim to regulate bodily movements by influencing the brain's chemical balance. Many individuals with moderate to severe head injuries undergo direct transfer from the emergency room to the operating room. In numerous cases, surgical intervention is necessary to remove substantial hematomas or contusions that exert pressure on the brain or increase intracranial pressure. Following surgery, close monitoring of these patients occurs in the intensive care unit (ICU).
Traumatic Brain Injury Market Dynamics
The landscape of traumatic brain injury (TBI) is poised to undergo significant changes in the upcoming years. TBI, often stemming from accidents or sports-related incidents, has garnered increased attention due to heightened awareness of its long-term effects and the imperative for enhanced diagnostics and therapies. A notable trend is the emergence of innovative diagnostic technologies, encompassing advanced imaging modalities and biomarker-based assessments, with a focus on early and precise TBI detection. This transition not only improves patient outcomes but also propels market growth as healthcare entities invest in these state-of-the-art diagnostic tools.
Moreover, the pharmaceutical sector is actively engaged in researching and developing novel therapeutics to address the intricate and multifaceted nature of TBI. This has fostered collaborations between biotech enterprises and academic entities, fostering a more dynamic market landscape. Government regulations and policies have significantly shaped the TBI market, with heightened awareness and advocacy efforts resulting in increased research funding, incentivizing companies to venture into this domain. Furthermore, the advent of telemedicine and remote monitoring technologies has facilitated enhanced TBI management and rehabilitation, bolstering healthcare accessibility, particularly for individuals in remote or underserved areas.
Nevertheless, several factors hinder the growth of the traumatic brain injury market. TBI encompasses a broad spectrum of injuries, ranging from mild concussions to severe trauma, posing challenges in diagnosis and treatment, necessitating tailored approaches for each case. The intricate nature of TBI impedes the development of universal solutions. Rigorous regulatory processes for medical devices and pharmaceuticals can delay the introduction of innovative TBI interventions, as meeting safety and efficacy standards entails a lengthy and costly process, deterring market entry for some companies.
Despite the heightened awareness of TBI, there remains a stigma surrounding mental health issues and cognitive impairments, leading to underreporting and delays in seeking medical assistance, hampering timely intervention. Additionally, the utilization of advanced technologies, such as wearable devices and telemedicine, raises concerns regarding data privacy and security, necessitating assurance for patients and healthcare providers regarding the safeguarding of sensitive health information.
Scope of the Traumatic Brain Injury Market Report
Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Traumatic Brain Injury Companies: Life Molecular Imaging SA, Hope Biosciences, Merz Pharmaceuticals GmbH, Vasopharm GmbH, Pinteon Therapeutics, Omniscient Neurotechnology, Pfizer, Supernus Pharmaceuticals, Inc., Solstice Neurosciences, Ipsen, POLYSAN Scientific & Technological Pharmaceutical Company, American CryoStem Corporation, and others
Key Traumatic Brain Injury Therapies: [18F]PI-2620, HB-adMSCs, NT 201, VAS203 (Ronopterin), PNT001, and others
Traumatic Brain Injury Therapeutic Assessment: Traumatic Brain Injury current marketed and Traumatic Brain Injury emerging therapies
Traumatic Brain Injury Market Dynamics: Traumatic Brain Injury market drivers and Traumatic Brain Injury market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Traumatic Brain Injury Unmet Needs, KOL's views, Analyst's views, Traumatic Brain Injury Market Access and Reimbursement
Table of Contents
1. Traumatic Brain Injury Market Report Introduction
2. Executive Summary for Traumatic Brain Injury
3. SWOT analysis of Traumatic Brain Injury
4. Traumatic Brain Injury Patient Share (%) Overview at a Glance
5. Traumatic Brain Injury Market Overview at a Glance
6. Traumatic Brain Injury Disease Background and Overview
7. Traumatic Brain Injury Epidemiology and Patient Population
8. Country-Specific Patient Population of Traumatic Brain Injury
9. Traumatic Brain Injury Current Treatment and Medical Practices
10. Traumatic Brain Injury Unmet Needs
11. Traumatic Brain Injury Emerging Therapies
12. Traumatic Brain Injury Market Outlook
13. Country-Wise Traumatic Brain Injury Market Analysis (2019–2032)
14. Traumatic Brain Injury Market Access and Reimbursement of Therapies
15. Traumatic Brain Injury Market Drivers
16. Traumatic Brain Injury Market Barriers
17. Traumatic Brain Injury Appendix
18. Traumatic Brain Injury Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Traumatic Brain Injury Pipeline
"Traumatic Brain Injury Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Traumatic Brain Injury market. A detailed picture of the Traumatic Brain Injury pipeline landscape is provided, which includes the disease overview and Traumatic Brain Injury treatment guidelines.
Traumatic Brain Injury Epidemiology
DelveInsight's 'Traumatic Brain Injury Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Traumatic Brain Injury epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market | Intrathecal Pumps Market | Hedgehog Pathway Inhibitors Market | Yellow Fever Market | Laryngeal Cancer Market | Female Infertility Market | Gender Dysphoria Market | Chronic Brain Damage Market | Spain Healthcare Outlook Market | Malignant Fibrous Histiocytoma Market | Asthma Diagnostic Devices Market | Chronic Obstructive Pulmonary Disease Treatment Devices Market | Airway Management Devices Market | Cough Assist Devices Market | Pulse Oximeters Market | Hemodialysis Catheter Devices Market | Chronic Spontaneous Urticaria Market | Gender Dysphoria Market | Germany Healthcare Outlook | Biopsy Devices Pipeline Insight | Bacterial Conjunctivitis Market | Infliximab Biosimilar Insight | Eosinophilic Asthma Market | Cushing Syndrome Market | Functional Dyspepsia Market | Peripherally Inserted Central Catheters (PICC) Devices Market
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: ...
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website:
Kritika Rehani
DelveInsight Business Research LLP
+1 469-945-7679
email us here
MENAFN03042024003118003196ID1108054750